1. Home
  2. QTWO vs GKOS Comparison

QTWO vs GKOS Comparison

Compare QTWO & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Q2 Holdings Inc.

QTWO

Q2 Holdings Inc.

HOLD

Current Price

$50.50

Market Cap

4.1B

Sector

Technology

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$120.91

Market Cap

6.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QTWO
GKOS
Founded
2004
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
6.9B
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
QTWO
GKOS
Price
$50.50
$120.91
Analyst Decision
Buy
Strong Buy
Analyst Count
13
14
Target Price
$86.25
$133.07
AVG Volume (30 Days)
1.3M
728.9K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
225.00
N/A
EPS
0.80
N/A
Revenue
$193,978,000.00
$507,442,000.00
Revenue This Year
$12.48
$23.29
Revenue Next Year
$10.16
$27.74
P/E Ratio
$60.00
N/A
Revenue Growth
N/A
32.33
52 Week Low
$46.16
$73.16
52 Week High
$95.10
$130.23

Technical Indicators

Market Signals
Indicator
QTWO
GKOS
Relative Strength Index (RSI) 35.68 56.24
Support Level N/A $78.93
Resistance Level $75.62 $130.23
Average True Range (ATR) 2.58 5.06
MACD 0.08 0.67
Stochastic Oscillator 32.82 88.63

Price Performance

Historical Comparison
QTWO
GKOS

About QTWO Q2 Holdings Inc.

Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: